Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Background: Multiple myeloma (MM) is the second most common hematological malignancy that still lacks effective clinical treatments. In particular, MM with central nervous system (CNS) invasion occurs ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Rate-splitting multiple access (RSMA) has emerged as a novel, general, and powerful framework for the design and optimization of non-orthogonal transmission, multiple access (MA), and interference ...

Both BMY’s Pomalyst and Revlimid are approved for multiple myeloma. Sanofi is also evaluating a fixed-dose subcutaneous (“SC”) formulation of Sarclisa for the treatment of R/R MM.

Multiple myeloma can be particularly challenging, because it adapts to treatments. According to Coach, “This cancer about every three years figures out the regiment and it comes back.” ...